Page last updated: 2024-11-12

ncx1000

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

2-methyl-3-(2-((4-nitrooxybutyloxy)carbonyl)vinyl)phenyl ursodeoxycholic acid ester: a nitric oxide donor; has been known in the literature as 2-(acetyloxy)benzoic acid 3-(nitrooxymethyl) phenyl ester, but this is an incomplete name [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID129628949
MeSH IDM0396949

Synonyms (16)

Synonym
ncx-1000
ncx 1000
2-methyl-3-(2-((4-nitrooxybutyloxy)carbonyl)vinyl)phenyl ursodeoxycholic acid ester
cholan-24-oic acid, 3,7-dihydroxy-, 2-methoxy-5-((1e)-3-(4- (nitrooxy)butoxy)-3-oxo-1-propenyl)phenyl ester, (3alpha,5beta,7beta)-
v9g7hr5l1q ,
401519-96-8
unii-v9g7hr5l1q
HY-U00023
CS-6761
no-ursodeoxycholic acid
301828-26-2
cholan-24-oic acid, 3,7-dihydroxy-, 2-methoxy-4-((1e)-3-(4-(nitrooxy)butoxy)-3-oxo-1-propen-1-yl)phenyl ester, (3.alpha.,5.beta.,7.beta.)-
,no-udca
[2-methoxy-4-[(e)-3-(4-nitrooxybutoxy)-3-oxoprop-1-enyl]phenyl] (4r)-4-[(3r,5s,7s,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoate
MS-31113
AKOS040744312

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Amiodarone led to a dose-dependent decrease in cell viability with an LD50 of 50 micromol/L and increased production of superoxide anion and lipid peroxidation."( Combining ursodeoxycholic acid or its NO-releasing derivative NCX-1000 with lipophilic antioxidants better protects mouse hepatocytes against amiodarone toxicity.
Chabli, A; Colin, P; Elimadi, A; Haddad, PS; Ouazzani-Chahdi, A; Spénard, J, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's10 (76.92)29.6817
2010's2 (15.38)24.3611
2020's1 (7.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (7.69%)5.53%
Reviews3 (23.08%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (69.23%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]